Cite
HARVARD Citation
Cameron, D. et al. (n.d.). Cost-effectiveness of first-line ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2. European journal of cancer. pp. S67-. [Online].